Loading…

Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage

Protein acetylation is a reversible process regulated by histone deacetylases (HDAC) that is often altered in human cancers. Suberoylanilide hydroxamic acid (SAHA) is the first HDAC inhibitor to be approved for clinical use as an anticancer agent. Given that histone acetylation is a key determinant...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2010-06, Vol.70 (11), p.4470-4480
Main Authors: CONTI, Chiara, LEO, Elisabetta, EICHLER, Gabriel S, SORDET, Olivier, MARTIN, Melvenia M, FAN, Angela, ALADJEM, Mirit I, POMMIER, Yves
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c610t-6ef4c39ccbfa154309328c236997dcfc7e86b235fd8afeed7a182d03bbc8cc2f3
cites cdi_FETCH-LOGICAL-c610t-6ef4c39ccbfa154309328c236997dcfc7e86b235fd8afeed7a182d03bbc8cc2f3
container_end_page 4480
container_issue 11
container_start_page 4470
container_title Cancer research (Chicago, Ill.)
container_volume 70
creator CONTI, Chiara
LEO, Elisabetta
EICHLER, Gabriel S
SORDET, Olivier
MARTIN, Melvenia M
FAN, Angela
ALADJEM, Mirit I
POMMIER, Yves
description Protein acetylation is a reversible process regulated by histone deacetylases (HDAC) that is often altered in human cancers. Suberoylanilide hydroxamic acid (SAHA) is the first HDAC inhibitor to be approved for clinical use as an anticancer agent. Given that histone acetylation is a key determinant of chromatin structure, we investigated how SAHA may affect DNA replication and integrity to gain deeper insights into the basis for its anticancer activity. Nuclear replication factories were visualized with confocal immunofluorescence microscopy and single-replicon analyses were conducted by genome-wide molecular combing after pulse labeling with two thymidine analogues. We found that pharmacologic concentrations of SAHA induce replication-mediated DNA damage with activation of histone gammaH2AX. Single DNA molecule analyses indicated slowdown in replication speed along with activation of dormant replication origins in response to SAHA. Similar results were obtained using siRNA-mediated depletion of HDAC3 expression, implicating this HDAC member as a likely target in the SAHA response. Activation of dormant origins was confirmed by molecular analyses of the beta-globin locus control region. Our findings demonstrate that SAHA produces profound alterations in DNA replication that cause DNA damage, establishing a critical link between robust chromatin acetylation and DNA replication in human cancer cells.
doi_str_mv 10.1158/0008-5472.can-09-3028
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2880188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20460513</sourcerecordid><originalsourceid>FETCH-LOGICAL-c610t-6ef4c39ccbfa154309328c236997dcfc7e86b235fd8afeed7a182d03bbc8cc2f3</originalsourceid><addsrcrecordid>eNpVUctu1DAUtRBVO5R-AsgbdqT4ESfOBmmUoXSkqpV4rK2bG3tqyNgjO23VJX9O0sdQVtdX53Hlcwh5x9kp50p_YozpQpW1OEUIBWsKyYR-RRZcSV3UZalek8Wec0Te5PxrWhVn6pAcCVZW01suyJ91uPadH30MNDp67vMYg6UrC2jH-wGypT7QFgLaRFs7DJl-H-Jdpqt4F-g3uxs8woP6LKbf-SNd4uhvYbQzI20hjPQq-Y0PEwShp-vQ3-AMXi7pCrawsW_JgYMh25OneUx-nn350Z4XF1df1-3yosCKs7GorCtRNoidA65KyRopNApZNU3do8Pa6qoTUrleg7O2r4Fr0TPZdagRhZPH5POj7-6m29oebRgTDGaX_BbSvYngzf9I8NdmE2-N0JpxrScD9WiAKeacrNtrOTNzJ2bO28x5m3Z5aVhj5k4m3fuXh_eq5xImwocnAmSEwaUpbZ__8YRW03dL-Rc8ipgn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage</title><source>Free E-Journal (出版社公開部分のみ)</source><creator>CONTI, Chiara ; LEO, Elisabetta ; EICHLER, Gabriel S ; SORDET, Olivier ; MARTIN, Melvenia M ; FAN, Angela ; ALADJEM, Mirit I ; POMMIER, Yves</creator><creatorcontrib>CONTI, Chiara ; LEO, Elisabetta ; EICHLER, Gabriel S ; SORDET, Olivier ; MARTIN, Melvenia M ; FAN, Angela ; ALADJEM, Mirit I ; POMMIER, Yves</creatorcontrib><description>Protein acetylation is a reversible process regulated by histone deacetylases (HDAC) that is often altered in human cancers. Suberoylanilide hydroxamic acid (SAHA) is the first HDAC inhibitor to be approved for clinical use as an anticancer agent. Given that histone acetylation is a key determinant of chromatin structure, we investigated how SAHA may affect DNA replication and integrity to gain deeper insights into the basis for its anticancer activity. Nuclear replication factories were visualized with confocal immunofluorescence microscopy and single-replicon analyses were conducted by genome-wide molecular combing after pulse labeling with two thymidine analogues. We found that pharmacologic concentrations of SAHA induce replication-mediated DNA damage with activation of histone gammaH2AX. Single DNA molecule analyses indicated slowdown in replication speed along with activation of dormant replication origins in response to SAHA. Similar results were obtained using siRNA-mediated depletion of HDAC3 expression, implicating this HDAC member as a likely target in the SAHA response. Activation of dormant origins was confirmed by molecular analyses of the beta-globin locus control region. Our findings demonstrate that SAHA produces profound alterations in DNA replication that cause DNA damage, establishing a critical link between robust chromatin acetylation and DNA replication in human cancer cells.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/0008-5472.can-09-3028</identifier><identifier>PMID: 20460513</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Breast Neoplasms - drug therapy ; Breast Neoplasms - enzymology ; Breast Neoplasms - genetics ; Cell Line, Tumor ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - enzymology ; Colonic Neoplasms - genetics ; DNA Damage ; DNA Replication - drug effects ; DNA, Neoplasm - biosynthesis ; DNA, Neoplasm - genetics ; Down-Regulation ; HCT116 Cells ; Histone Deacetylase Inhibitors - pharmacology ; Histone Deacetylases - deficiency ; Histone Deacetylases - genetics ; Histone Deacetylases - metabolism ; Histones - biosynthesis ; Humans ; Hydroxamic Acids - pharmacology ; Medical sciences ; Pharmacology. Drug treatments ; Tumors ; Vorinostat</subject><ispartof>Cancer research (Chicago, Ill.), 2010-06, Vol.70 (11), p.4470-4480</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 AACR.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c610t-6ef4c39ccbfa154309328c236997dcfc7e86b235fd8afeed7a182d03bbc8cc2f3</citedby><cites>FETCH-LOGICAL-c610t-6ef4c39ccbfa154309328c236997dcfc7e86b235fd8afeed7a182d03bbc8cc2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22853094$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20460513$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CONTI, Chiara</creatorcontrib><creatorcontrib>LEO, Elisabetta</creatorcontrib><creatorcontrib>EICHLER, Gabriel S</creatorcontrib><creatorcontrib>SORDET, Olivier</creatorcontrib><creatorcontrib>MARTIN, Melvenia M</creatorcontrib><creatorcontrib>FAN, Angela</creatorcontrib><creatorcontrib>ALADJEM, Mirit I</creatorcontrib><creatorcontrib>POMMIER, Yves</creatorcontrib><title>Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Protein acetylation is a reversible process regulated by histone deacetylases (HDAC) that is often altered in human cancers. Suberoylanilide hydroxamic acid (SAHA) is the first HDAC inhibitor to be approved for clinical use as an anticancer agent. Given that histone acetylation is a key determinant of chromatin structure, we investigated how SAHA may affect DNA replication and integrity to gain deeper insights into the basis for its anticancer activity. Nuclear replication factories were visualized with confocal immunofluorescence microscopy and single-replicon analyses were conducted by genome-wide molecular combing after pulse labeling with two thymidine analogues. We found that pharmacologic concentrations of SAHA induce replication-mediated DNA damage with activation of histone gammaH2AX. Single DNA molecule analyses indicated slowdown in replication speed along with activation of dormant replication origins in response to SAHA. Similar results were obtained using siRNA-mediated depletion of HDAC3 expression, implicating this HDAC member as a likely target in the SAHA response. Activation of dormant origins was confirmed by molecular analyses of the beta-globin locus control region. Our findings demonstrate that SAHA produces profound alterations in DNA replication that cause DNA damage, establishing a critical link between robust chromatin acetylation and DNA replication in human cancer cells.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - enzymology</subject><subject>Breast Neoplasms - genetics</subject><subject>Cell Line, Tumor</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - enzymology</subject><subject>Colonic Neoplasms - genetics</subject><subject>DNA Damage</subject><subject>DNA Replication - drug effects</subject><subject>DNA, Neoplasm - biosynthesis</subject><subject>DNA, Neoplasm - genetics</subject><subject>Down-Regulation</subject><subject>HCT116 Cells</subject><subject>Histone Deacetylase Inhibitors - pharmacology</subject><subject>Histone Deacetylases - deficiency</subject><subject>Histone Deacetylases - genetics</subject><subject>Histone Deacetylases - metabolism</subject><subject>Histones - biosynthesis</subject><subject>Humans</subject><subject>Hydroxamic Acids - pharmacology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumors</subject><subject>Vorinostat</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNpVUctu1DAUtRBVO5R-AsgbdqT4ESfOBmmUoXSkqpV4rK2bG3tqyNgjO23VJX9O0sdQVtdX53Hlcwh5x9kp50p_YozpQpW1OEUIBWsKyYR-RRZcSV3UZalek8Wec0Te5PxrWhVn6pAcCVZW01suyJ91uPadH30MNDp67vMYg6UrC2jH-wGypT7QFgLaRFs7DJl-H-Jdpqt4F-g3uxs8woP6LKbf-SNd4uhvYbQzI20hjPQq-Y0PEwShp-vQ3-AMXi7pCrawsW_JgYMh25OneUx-nn350Z4XF1df1-3yosCKs7GorCtRNoidA65KyRopNApZNU3do8Pa6qoTUrleg7O2r4Fr0TPZdagRhZPH5POj7-6m29oebRgTDGaX_BbSvYngzf9I8NdmE2-N0JpxrScD9WiAKeacrNtrOTNzJ2bO28x5m3Z5aVhj5k4m3fuXh_eq5xImwocnAmSEwaUpbZ__8YRW03dL-Rc8ipgn</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>CONTI, Chiara</creator><creator>LEO, Elisabetta</creator><creator>EICHLER, Gabriel S</creator><creator>SORDET, Olivier</creator><creator>MARTIN, Melvenia M</creator><creator>FAN, Angela</creator><creator>ALADJEM, Mirit I</creator><creator>POMMIER, Yves</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20100601</creationdate><title>Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage</title><author>CONTI, Chiara ; LEO, Elisabetta ; EICHLER, Gabriel S ; SORDET, Olivier ; MARTIN, Melvenia M ; FAN, Angela ; ALADJEM, Mirit I ; POMMIER, Yves</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c610t-6ef4c39ccbfa154309328c236997dcfc7e86b235fd8afeed7a182d03bbc8cc2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - enzymology</topic><topic>Breast Neoplasms - genetics</topic><topic>Cell Line, Tumor</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - enzymology</topic><topic>Colonic Neoplasms - genetics</topic><topic>DNA Damage</topic><topic>DNA Replication - drug effects</topic><topic>DNA, Neoplasm - biosynthesis</topic><topic>DNA, Neoplasm - genetics</topic><topic>Down-Regulation</topic><topic>HCT116 Cells</topic><topic>Histone Deacetylase Inhibitors - pharmacology</topic><topic>Histone Deacetylases - deficiency</topic><topic>Histone Deacetylases - genetics</topic><topic>Histone Deacetylases - metabolism</topic><topic>Histones - biosynthesis</topic><topic>Humans</topic><topic>Hydroxamic Acids - pharmacology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumors</topic><topic>Vorinostat</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CONTI, Chiara</creatorcontrib><creatorcontrib>LEO, Elisabetta</creatorcontrib><creatorcontrib>EICHLER, Gabriel S</creatorcontrib><creatorcontrib>SORDET, Olivier</creatorcontrib><creatorcontrib>MARTIN, Melvenia M</creatorcontrib><creatorcontrib>FAN, Angela</creatorcontrib><creatorcontrib>ALADJEM, Mirit I</creatorcontrib><creatorcontrib>POMMIER, Yves</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CONTI, Chiara</au><au>LEO, Elisabetta</au><au>EICHLER, Gabriel S</au><au>SORDET, Olivier</au><au>MARTIN, Melvenia M</au><au>FAN, Angela</au><au>ALADJEM, Mirit I</au><au>POMMIER, Yves</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>70</volume><issue>11</issue><spage>4470</spage><epage>4480</epage><pages>4470-4480</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Protein acetylation is a reversible process regulated by histone deacetylases (HDAC) that is often altered in human cancers. Suberoylanilide hydroxamic acid (SAHA) is the first HDAC inhibitor to be approved for clinical use as an anticancer agent. Given that histone acetylation is a key determinant of chromatin structure, we investigated how SAHA may affect DNA replication and integrity to gain deeper insights into the basis for its anticancer activity. Nuclear replication factories were visualized with confocal immunofluorescence microscopy and single-replicon analyses were conducted by genome-wide molecular combing after pulse labeling with two thymidine analogues. We found that pharmacologic concentrations of SAHA induce replication-mediated DNA damage with activation of histone gammaH2AX. Single DNA molecule analyses indicated slowdown in replication speed along with activation of dormant replication origins in response to SAHA. Similar results were obtained using siRNA-mediated depletion of HDAC3 expression, implicating this HDAC member as a likely target in the SAHA response. Activation of dormant origins was confirmed by molecular analyses of the beta-globin locus control region. Our findings demonstrate that SAHA produces profound alterations in DNA replication that cause DNA damage, establishing a critical link between robust chromatin acetylation and DNA replication in human cancer cells.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>20460513</pmid><doi>10.1158/0008-5472.can-09-3028</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2010-06, Vol.70 (11), p.4470-4480
issn 0008-5472
1538-7445
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2880188
source Free E-Journal (出版社公開部分のみ)
subjects Antineoplastic agents
Biological and medical sciences
Breast Neoplasms - drug therapy
Breast Neoplasms - enzymology
Breast Neoplasms - genetics
Cell Line, Tumor
Colonic Neoplasms - drug therapy
Colonic Neoplasms - enzymology
Colonic Neoplasms - genetics
DNA Damage
DNA Replication - drug effects
DNA, Neoplasm - biosynthesis
DNA, Neoplasm - genetics
Down-Regulation
HCT116 Cells
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylases - deficiency
Histone Deacetylases - genetics
Histone Deacetylases - metabolism
Histones - biosynthesis
Humans
Hydroxamic Acids - pharmacology
Medical sciences
Pharmacology. Drug treatments
Tumors
Vorinostat
title Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T02%3A51%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20Histone%20Deacetylase%20in%20Cancer%20Cells%20Slows%20Down%20Replication%20Forks,%20Activates%20Dormant%20Origins,%20and%20Induces%20DNA%20Damage&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=CONTI,%20Chiara&rft.date=2010-06-01&rft.volume=70&rft.issue=11&rft.spage=4470&rft.epage=4480&rft.pages=4470-4480&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/10.1158/0008-5472.can-09-3028&rft_dat=%3Cpubmed_cross%3E20460513%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c610t-6ef4c39ccbfa154309328c236997dcfc7e86b235fd8afeed7a182d03bbc8cc2f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/20460513&rfr_iscdi=true